Background
==========

Gastric cancer (GC) is the second leading cause of death from malignant tumor worldwide \[[@B1]-[@B3]\], and more than 40% of the world GC cases occur in China \[[@B4]\]. Takahashi *et al*. \[[@B2]\] reported that there were approximately 989,000 new cases of GC and 738,000 deaths worldwide. Increasing early diagnosis of GC has improved the survival rate. However, the prognosis for recurrent or unresectable GC remains poor \[[@B2]\]. Various chemotherapy regimens have been developed for advanced gastric cancer (AGC) patients based on the understanding that chemotherapy can increase the length and quality of life \[[@B5]\].

S-1 is an orally active derivative of 5-FU, which is a fourth generation oral fluoropyrimidine \[[@B3],[@B6]\], and the drug has been used instead of 5-FU in some clinical trials \[[@B3],[@B7],[@B8]\]. Oxaliplatin is typically administered with fluorouracil and leucovorin in a combination known as FOLFOX for the treatment of GC \[[@B5]\]. Previously, clinical studies have reported that S-1 in combination with oxaliplatin has a high response rate ranging from 53 to 59% and an excellent toxicity profile in the treatment of advanced gastric cancer \[[@B9]-[@B11]\]. Recently, two phase II trials have proven the efficacy and safety profile of the SOX regimen as a first-line treatment for advanced gastric cancer in Korean and China patients. Patients enrolled in these studies exhibited favorable efficacy and tolerance \[[@B12],[@B13]\].

Cetuximab is a recombinant, human/chimeric IgG1 monoclonal antibody (mAb) directed against the epidermal growth factor receptor (EGFR) \[[@B14]\]. Cetuximab has been proven to be effective as a single agent, improving overall survival (OS) in metastatic colorectal cancer \[[@B15]\] and providing meaningful benefit in advanced head and neck cancer \[[@B16]\]. Cetuximab binds to the extracellular domain of EGFR, thus leading to inhibition of its downstream signaling. EGFR is a transmembrane tyrosine kinase receptor that, on ligand binding, triggers two main signaling pathways, including the RAS-RAF-MAPK and the PI3K-PTEN-AKT pathway \[[@B17]\].

Cetuximab has been evaluated in many phase II studies in patients with advanced GC either as monotherapy or combined with chemotherapy. In the first-line metastatic setting, several trials have evaluated combinations of cetuximab with different chemotherapy regimens \[[@B18]-[@B22]\] and all have reported encouraging objective response rates (ORRs) of 40 to 69% and median overall survival (OS) of 9.5 to 17 months. Toxicities have generally been consistent with the additive toxicities of cetuximab and the respective chemotherapy regimens. Grade 3/4 toxicities included neutropenia in 6 to 46% of patients, diarrhea in 4 to 33% of patients, skin toxicity in 6 to 24% of patients, and anaphylaxis to cetuximab in \<5% of patients. Furthermore, the combination of cetuximab and FOLFOX4 is effective and well tolerated for AGC \[[@B23]\].

Epidermal growth factor receptor has been found to be overexpressed in gastric cancer \[[@B24],[@B25]\]. Although colorectal tumors with an activating mutation of the Kirsten(K)-ras gene are not sensitive to EGFR antibodies \[[@B26]\], the incidence of K-ras mutations in gastric cancer appears to be low \[[@B27]-[@B29]\]. However, no clinical trial has investigated the effect of cetuximab combined with SOX regimen for Chinese patients with AGC. In our study, we investigated the efficacy and safety of cetuximab plus SOX therapy in Chinese patients with AGC.

Methods
=======

Patients
--------

Fifty-six patients with histologically or cytologically proven unresectable gastric cancer or recurrence post-operation were enrolled. All of the patients had at least one measurable lesion by the Response Evaluation Criteria in Solid Tumors (RECIST) criteria, were ECOG performance status (PS) 0 to 2 and had anticipated life expectancies \>3 months. Additionally, the patients were required to be chemotherapy naive or more than 6 months past the last adjuvant chemotherapy and to possess favorable bone marrow reservation (hemoglobin ≥80 g/L, platelet count ≥100 × 10^9^, leukocyte count = 3 to 10 × 10^9^, neutrophil count ≥1.5 × 10^9^). Laboratory examination showed adequate liver function (total bilirubin ≤1.5 times the upper limit, ALT/AST ≤2.5 times the upper limit) and renal function (blood creatinine ≤ 1.5 mg/dL, creatinine clearance ≥50 mL/min). All patients provided written informed consent and this study was approved by Institutional Review Board of Henna Cancer hospital. All eligible patients were enrolled in this study between 1 August 2010 and 30 September 2012, and were randomly assigned into either the control group (26 patients) or the experimental group (30 patients).

Treatments
----------

For patients in the experimental group, once-weekly cetuximab (400 mg/m^2^ at the first infusion then 250 mg/m^2^ every week) was administered. For patients in both the control and experimental groups, oxaliplatin (100 mg/m^2^) was administered intravenously on day 1. S-1 (80 mg/m^2^/day) was given orally twice daily for 14 days. All patients then took one week's rest before the next cycle. Physical examination and blood analysis were performed at each cycle during chemotherapy. Responses of chemotherapy were assessed according to the RECIST criteria. Responses were classified as complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD). Response rate was calculated as the sum of CR and PR. The disease-control rate was the sum of CR, PR, and SD. Six cycles of chemotherapy were given to all patients who showed response. Computed tomography and magnetic resonance imaging were used to assess tumor size. Second-line chemotherapy was given to patients who did not show response to the SOX or SOX + cetuximab (Ce-SOX) treatment. For grade 3/4 adverse events, the chemotherapy dose could be reduced if the symptoms were alleviated after management. Chemotherapy could be postponed if a patient's condition still did not meet the criteria for chemotherapy treatment after adverse-event management.

Patients were followed up every 3 months until death or until the cutoff date of this study on 30 September 2012. The response rate (RR) was calculated as CR plus PR, time to progression (TTP) was defined as the period from the time of initial chemotherapy to PD and OS was defined as the period from the time of initial chemotherapy to death or the time of the final follow-up. Toxicity was assessed as grade 1 to 4 according to the US National Cancer Institute's Terminology Criteria for Adverse Events V3.0.

Statistical analysis
--------------------

Statistical analyses were conducted using SPSS 13.0 software. Progression-free survival (PFS) was calculated from the date of randomization to the time of disease progression, death, or September 30, 2012. PFS and OS were analyzed using the Kaplan-Meier method. The chi-squared test was used to compare the differences between groups. Results with *P* \<0.05 were regarded as statistically significant.

Results
=======

Patients' characteristics
-------------------------

Fifty-six patients were enrolled onto our study from August 2010 to September 2012. Patient characteristics are displayed in Table [1](#T1){ref-type="table"}. There were 37 males and 19 females with median age 49 years (range 26 to 78) and the PS was zero or one in 50 patients. The median number of metastatic sites was two, and all of the patients presented with more than two metastatic sites. There were no statistically significant differences in the baseline characteristics between the two groups.

###### 

Demographic data of Chinese patients

  **Characteristic**        **Number of patients**   **%**
  ------------------------- ------------------------ -------
  Median age (range)        56 (26 to 78)             
  Gender                                              
  Male                      37                       66.1
  Female                    19                       33.9
  ECOG performance status                             
  0                         3                        5.4
  1                         47                       83.9
  2                         6                        10.7
  Primary tumor                                       
  Resected                  12                       21.4
  Unresected                44                       78.6
  Histology                                           
  Diffuse                   31                       55.4
  Intestinal                25                       44.6
  Sites of metastasis                                 
  Lymph nodes               41                       73.2
  Liver                     23                       41.1
  Lung                      3                        5.4
  Peritoneum                8                        14.3
  Other                     19                       33.9

Treatment efficacy
------------------

The 30 patients in the Ce-SOX group received an average of 3.47 cycles of chemotherapy treatment while the 26 patients in the SOX group received an average of 3.62 cycles of chemotherapy treatment. There was no statistically significant difference in the average chemotherapy cycles received by patients between the Ce-SOX and SOX groups (*P* = 0.071). The response rate in the Ce-SOX group was 54.8%, which was higher than the 44.0% in the SOX group, but failed to demonstrate statistical significance (*P* = 0.22, χ2 = 3.18). The disease-control rate of the Ce-SOX group and SOX group was 87.1% and 76.0%, respectively (*P* = 0.16, χ2 = 2.98) (Table [2](#T2){ref-type="table"}).

###### 

**Response rates of** c**etuximab in combination with S-1 and oxaliplatin (Ce-SOX) and S-1 and oxaliplatin (SOX) groups**

  **Response**               **Ce-SOX**   **SOX**   ***P***
  -------------------------- ------------ --------- ---------
  Complete response          1            0         \-
  Partial response           16           11        0.11
  Stable disease             10           8         0.18
  Progressive disease        4            6         0.15
  Response rate (%)          54.8         44.0      0.22
  Disease control rate (%)   87.1         76.0      0.16

Patients were followed up for 2 years until this study ended. Median PFS in the Ce-SOX group was statistically higher than that in the SOX group (12.8 versus 10.1 months, *P* = 0.007, χ2 = 10.217) (Figure [1](#F1){ref-type="fig"}). The median OS of the Ce-SOX group and SOX group was 14.0 and 12.2 months, respectively (*P* = 0.043) (Figure [2](#F2){ref-type="fig"}). The one-year survival rate for the Ce-SOX group was 57% compared to 40% in the SOX group. The results indicated that the Ce-SOX group showed significant benefits in PFS and OS.

![**Progression-free survival of patients in the Ce-SOX group and the SOX group estimated by Kaplan--Meier.** Cum, cumulative.](1477-7819-12-115-1){#F1}

![**Kaplan-Meier curve for overall survival of patients in the Ce-SOX group and the SOX group.** Cum, cumulative.](1477-7819-12-115-2){#F2}

Safety assessment
-----------------

The observed hematological and nonhematological toxicities are shown in Table [3](#T3){ref-type="table"}. The major hematological toxicities were thrombocytopenia and neutropenia. The most common grade 3/4 adverse events included bone marrow suppression, which leads to thrombocytopenia and neutropenia. There was no statistically significant difference in the incidences of adverse effects between the two groups in the hematological toxicities (Table [3](#T3){ref-type="table"}). Among the nonhematological toxicities, nausea, vomiting, and diarrhea were also observed. Other recorded grade 1/2 adverse events were peripheral neuropathy, hepatic dysfunction, and renal dysfunction. There was no statistical difference in the grade 3 or 4 adverse effects between the two groups, included neutropenia (26.7 versus 34.6%), thrombocytopenia (6.6 versus 7.7%), nausea and vomiting (3.3 versus 7.7%), diarrhea (0 versus 3.8%), peripheral neuropathy (3.3 versus 0%), hepatic dysfunction (0 versus 3.8%), and hand-foot syndrome (3.3 versus 3.8%). No treatment-related deaths were recorded.

###### 

Incidence of hematological and nonhematological toxicities

  **Type of toxicity**    **Grade 1 to 2**   **Grade 3 to 4**                                   
  ----------------------- ------------------ ------------------ ------- ----------- ----------- ------
  Hematological           22 (73.3)          17 (65.4)          0.52    10 (33.3)   11 (42.3)   0.58
  Thrombocytopenia        6 (20.0)           5 (19.2)           0.94    2 (6.6)     2 (7.7)     1.0
  Neutropenia             16 (53.3)          12 (46.2)          0.59    8 (26.7)    9 (34.6)    0.57
  Nonhematological        16 (53.3)          21 (80.8)          0.03    3 (10.0)    5 (19.2)    0.53
  Nausea and vomiting     1 (3.3)            8 (30.8)           0.008   1 (3.3)     2 (7.7)     0.59
  Diarrhea                0 (0)              1 (3.8)            0.46    0 (0)       1 (3.8)     0.46
  Mucositis               1 (3.3)            2 (7.7)            0.59    0 (0)       0 (0)       \-
  Hand-foot syndrome      2 (6.7)            1 (3.8)            0.55    1 (3.3)     1 (3.8)     1.0
  Peripheral neuropathy   8 (26.7)           1 (3.8)            0.029   1 (3.3)     0 (0)       0.68
  Hepatic dysfunction     3 (10.0)           2 (7.7)            0.67    0 (0)       1 (3.8)     0.72
  Renal dysfunction       1 (3.3)            6 (23.1)           0.04    0 (0)       0 (0)       \-

Discussion
==========

Gastric cancer is the second most frequent cancer in the world. Approximately 84% of gastric cancer patients will have advanced disease, and median survival of these patients without chemotherapy is only 3 to 4 months \[[@B30]\]. For advanced-stage gastric cancer, chemotherapy is usually the most effective treatment option. However, the 5-year survival rate for gastric cancer is just 20% \[[@B31]\], and the prognosis of patients with AGC is still poor. Therefore, it would be interesting to investigate new combinations and to include drugs directed against new therapeutic targets in the setting. Cetuximab, which targets human EGFR, has demonstrated promising results in treating advanced gastric cancer \[[@B1],[@B18]-[@B22],[@B32]\]. In this study, we investigated the efficacy and safety of cetuximab with the SOX regimen in advanced gastric cancer.

In first-line setting cetuximab has been evaluated in combination with different regimens of chemotherapy. Lordick *et al*. \[[@B19]\] found that cetuximab plus FUFOX showed an interestingly high response rate in metastatic gastric cancer. The results showed that TTP was 7.6 months (CI 95%: 5.0 to 10.1 months) and OS was 9.5 months (CI 95%: 7.9 to 11.1 months). Pinto *et al*. \[[@B21]\] demonstrated that the addition of cetuximab to the cisplatin/docetaxel regimen improved the ORR of the cisplatin/docetaxel doublet in the first-line treatment of advanced gastric cancer. In addition, cetuximab combined with FOLFOX4 was very active with an acceptable toxicity profile \[[@B23]\]. The results showed that ORR and DCR were 36.0% (95% CI = 17 to 55%) and 84.0% (95% CI = 70 to 98%), respectively. The median PFS was 6.5 months (95% CI = 5.0 to 8.0 months) and median OS was 10.6 months (95% CI = 4.4 to 16.7 months). Based on these promising results, a phase III clinical trial was conducted \[[@B33]\]. In the randomized, open-label, and multicenter EXPAND trial, the investigators studied the combination of capecitabine and cisplatin as a first line treatment in advanced GC and gastro-esophageal junction (GEJ) cancer with or without cetuximab. This study enrolled 904 patients with unresectable advanced GC or GEJ cancer who had not received any prior treatment with chemotherapy or radiotherapy. However, the study unfortunately did not meet the primary endpoint of an improvement in PFS (4.4 versus 5.6 months), did not increase the OS (9.4 versus 10.7 months), and showed no significant differences in RR (29 versus 30%) with and without cetuximab, respectively. Data from the EXPAND study suggested that addition of EGFR antibodies did not provide additional benefit compared with chemotherapy alone. This absence of efficacy might be due to choosing capecitabine-cisplatin as the chemotherapy backbone \[[@B33]\].

The SOX regimen has been evaluated in several clinical studies. Koizumi *et al*. \[[@B10]\] reported that SOX regimen with oxaliplatin at a dose of 100 mg/m^2^ was effective and well tolerated in AGC patients. In their study, the median PFS time was 6.5 months, the one-year survival rate was 71%, and the median survival time was 16.5 months. Moreover, a lower incidence of grade 3/4 toxicity with SOX regimen was also observed. These results indicated that SOX regimen is more tolerable and tends to be superior to S-1 plus cisplatin \[[@B8]\] in terms of safety. Li and Chen \[[@B34]\] also evaluated the combination of S-1 and oxaliplatin in a Phase II trial. In this trial, 66 patients with AGC were enrolled. Grade 3/4 anemia and neutropenia was observed in 6.4% of patients, and GI toxicities such as nausea, anorexia, and liver dysfunction were observed in 12.5%, 5.4%, and 9.7%, respectively. It was concluded from this study that the SOX regimen as a neoadjuvant treatment was associated with high efficacy and acceptable side effects. Similarly, Oh *et al*. \[[@B12]\] and Liu *et al*. \[[@B13]\] also demonstrated that the SOX regimen evidenced a relatively high response rate and was well tolerated with less toxicity and more convenient treatment as a first-line therapy for AGC patients.

In 2013, Liu *et al.*\[[@B35]\] conducted a trial using the SOX regimen (S-1 was administered orally, 40 mg/ (m^2^ · d), b.i.d., with a schedule of 14 days on and 7 days off, while oxaliplatin was administered 130 mg/m^2^ on day 1.) that showed there were 2 (5.26%) CR, 12 (31.58%) PR, 15 (39.47%) SD, and 9 (23.68%) PD. The overall response rate and the disease control rate (DCR) was 36.84 and 76.31%, respectively. The TTP was 7.9 months. The median survival time (MST) was 10.2 months. These results demonstrated that the SOX regimen was effective and tolerable in the treatment of patients with AGC. The similar efficacies with less toxicity of SOX regimen in the other two studies indicate that the SOX regimen has the potential to replace current regimens \[[@B36],[@B37]\]. In the present study, we performed the Ce-SOX regimen and the SOX regimen (as control) for advanced gastric cancer. In the SOX regimen, the results of efficacy and safety were similar to the previous studies. In the Ce-SOX regimen, median PFS and median OS in the Ce-SOX regimen were statistically higher compared with the SOX regimen (12.8 versus 10.1 months (*P* = 0.007), 14.0 versus 12.2 months (*P* = 0.043), respectively). The one-year survival rate for the Ce-SOX group was 57% compared to 40% in the SOX group. These results suggest that cetuximab in combination with the SOX regimen shows significant therapeutic benefits to the Chinese patients with AGC. However, this study is limited by its small sample size. Future randomized, double-blind, large-scale clinical trials are warranted to clarify the role of this regimen in advanced gastric cancer.

Conclusions
===========

In conclusion, our study showed that cetuximab combined with the SOX regimen gave a favorable efficacy and safety profile in Chinese patients with advanced gastric cancer. Compared with the SOX regimen, this new regimen exerts significant therapeutic benefits to Chinese patients with advanced gastric cancer.
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